Skip to content
RockstarTopical Botanical Blends

Blog

Vaginal Dryness in Menopause & Botanicals | What the Science Shows

Cross section of vaginal skin tissue and cannabinoid receptor workings

Heather Reilly Hiemstra is a Certified Menopause Coach, independent researcher, educator, speaker and founder of Rockstar Blends.

On this page

What does the science have to say about using botanicals right down there?

Many women come here looking for natural help with a problem that doesn't get talked about politely - vaginal dryness in menopause. Our tissues have changed. Lubrication isn't what it was. Maybe its harder to focus. Maybe sex hurts in ways that diminish desire, confidence and the list goes on.

Most end up asking some version of the same question as the practitioners I work with — naturopaths, nurses, midwives, menopause specialists — what does the research on topical botanicals show?

So let's start at the beginning, with the short version. The compounds in this post are documented in peer-reviewed research. What hasn't been done is the clinical work that would connect them to vaginal tissue in menopause, and this post shows exactly where that line falls. It begins with one fact that changes everything: vaginal mucosa is not skin.

Why mucosa is the opposite of skin

In the CBD Roll-On post I talked for awhile about the stratum corneum — the dense, ordered, brick-and-mortar lipid architecture that makes the skin a remarkable barrier. Vaginal mucosa is a different problem entirely.

Vaginal mucosa is still stratified epithelium, but the surface is hydrated and lacks the ordered lipid matrix that defines skin's barrier function. Mucosal tissue is built for exchange — it's the body's interface for absorption, immunity, and secretion. That changes the pharmacology in three important ways.

First, delivery is meaningfully more efficient. In the pharmaceutical sciences literature, the vaginal route has been characterized as more efficient than transdermal delivery for many lipophilic compounds — it's an established route for hormone delivery, antifungal delivery, and several systemic drug routes precisely because mucosa accepts what skin resists.

Second, the formulation problem inverts. On skin, the challenge is getting compounds through a barrier that is built to keep them out. On mucosa, the challenge is delivering compounds at an effective concentration without irritation to tissue that is more permeable, more vascular, and, in menopausal women, often thinner and more reactive than it used to be.

Third, what's underneath the surface matters more than ever. Once a compound is through, it encounters a tissue rich in endocannabinoid system receptors and the immune-cell populations that express them.

Cross section of vaginal skin tissue and cannabinoid receptor workings

The endocannabinoid system in vaginal and vulvar tissue

The endocannabinoid system is a signaling network expressed throughout the body. It's the system your body uses to manage pain, inflammation, immune response, mood, sleep, appetite, reproductive function, and tissue homeostasis. It operates through two primary receptor types: CB1, concentrated in the central and peripheral nervous system, and CB2, concentrated in immune tissue and at sites of inflammation. The system makes its own ligands — anandamide and 2-arachidonoylglycerol, or 2-AG, the one I call the Rockstar molecule — and breaks them down with its own enzymes.

Both CB1 and CB2 receptors have been characterized in the female reproductive system, including in the ovaries, uterus, fallopian tube, and broader urogenital tissue, with CB1 protein expression demonstrated by immunohistochemistry in the smooth muscle and luminal epithelium of human fallopian tube specifically[1][2]. CB2 is expressed on the mast cells, macrophages, and lymphocytes that populate mucosal tissue throughout the body — best characterized in the gut and respiratory mucosa — where the receptor regulates degranulation and local inflammatory tone[3]. CB1 and CB2 are also expressed on peripheral nerve terminals, where they modulate neuropeptide release and nociceptive signaling[3].

Direct, vaginal-tissue-specific cannabinoid receptor work is a more recent and smaller body of research. A 2025 study in Biomolecules demonstrated that CB1 receptor activation regulates vaginal secretion in a murine model — establishing that functional cannabinoid receptors are present and signaling in vaginal tissue, while also documenting that chronic systemic CB1 activation reduces basal vaginal moisture[4]. That last detail matters: it is consistent with the longstanding clinical observation that some women who use cannabis systemically report vaginal dryness. It is a finding about systemic, chronic, full-agonist CB1 activation throughout the body. The study confirms that the receptor system is there and functionally responsive in this tissue. The implications for a topical application are not the same as the implications for inhaled or oral cannabis use.

Beyond the murine vaginal-secretion work, the broader cannabinoid-in-gynecology literature has characterized CB1 and CB2 expression across female reproductive tissues[1][5]. The receptor mechanisms are well-supported for the class. The compound pharmacology is well-supported for the class. What is not yet published is a dedicated pharmacokinetic study quantifying how much CBD or β-caryophyllene, applied in an oil-based botanical, reaches the receptor populations in this tissue at a concentration sufficient to act. I'll come back to this.

So, what is Rockstar Woman Entourage?

A leave-on botanical oil for the vulva and labia, with full spectrum hemp and copaiba among its nine whole-plant ingredients. The extraction methods are matched to the compounds — CO₂ where CO₂ is needed, essential oil where essential oil is appropriate.

What's in the bottle?

Rockstar Woman Entourage is a 30ml fractionated coconut oil base carrying a full-spectrum hemp extract and a defined botanical stack.

Fractionated coconut oil Carrier.

Full-spectrum hemp extract Whole-plant cannabinoids, native terpenes and flavonoids, with CBD dominant.

Copaiba essential oil β-caryophyllene, a CB2-selective agonist in the published cannabinoid literature.

Ginger CO₂ extract Gingerols and shogaols, CO₂-extracted.

Frankincense serrata CO₂ AKBA, a 5-lipoxygenase inhibitor. (AKBA content in the current batch is pending HPLC confirmation — see the section below.)

German Chamomile CO₂ Chamazulene — the deep-blue compound also visible in Roll On Entourage.

Ylang Ylang & Sweet Orange Additional monoterpene activity and the sensory profile of the formula.

Vanilla extracts Vanillin and the broader vanilla fraction.

Why each ingredient is there

Fractionated coconut oil FCO is the carrier. The fractionation process concentrates the medium-chain fatty acid fraction and removes the longer-chain triglycerides that make whole coconut oil solid at room temperature.

Full-spectrum hemp extract As in Rockstar Roll On Entourage, this is whole-plant extract — the full phytochemical profile, including CBD, the minor cannabinoids present in trace amounts, the plant's own terpene fraction, and the flavonoid compounds that accompany them. The published comparative research on whole-plant extract versus isolated CBD has documented different dose-response profiles for inflammation between the two preparations, with the whole-plant extract showing a more linear and predictable response across a range of doses while isolated CBD showed a narrower effective window[6]. That work was done with systemic administration in an animal model rather than topical application. This is consistent with the broader entourage-effect framework[7], which is supported by directional evidence, not by settled fact. In Rockstar Woman Entourage the hemp extract goes in first, before any of the botanicals, as the foundation of the formula.

Copaiba essential oil. Copaiba is dominated by β-caryophyllene (BCP), and BCP has been characterized in published research as a selective CB2 receptor agonist with documented action in animal and in-vitro studies[8].

Ginger CO₂ The CO₂ extract is used rather than the steam-distilled essential oil because CO₂ extraction yields the full gingerol and shogaol fraction — steam distillation does not capture these compounds at the same concentration.

Frankincense serrata CO₂ Boswellia serrata contributes AKBA — acetyl-11-keto-β-boswellic acid — which has been characterized as a selective 5-lipoxygenase inhibitor. The CO₂ extraction method matters here for the same reason it matters in Roll On Entourage: steam distillation cannot capture the boswellic acid fraction, but CO₂ extraction can.

One open item worth disclosing. The certificate of analysis on the specific frankincense serrata CO₂ source used in current production was performed by GC-MS, which is an analytical method that cannot detect boswellic acids. HPLC analysis is required to confirm AKBA concentration in this specific extract. The CO₂ extraction method is the correct method for AKBA recovery, the supplier is a well-regarded specialty botanical extractor, and the literature on Boswellia serrata CO₂ extracts is consistent. But until we have HPLC data, the AKBA content of this exact ingredient is supported as a class effect rather than confirmed for the bottle on your shelf. We're working on it.

The supporting botanical layer. German chamomile CO₂ at 0.5% contributes chamazulene — the same deep blue compound visible in the Roll On Entourage bottle. Ylang ylang essential oil at 0.5% and sweet orange essential oil at 0.67% contribute additional monoterpene activity and the sensory profile of the formula. Vanilla botanical extract contributes vanillin and the broader vanilla phytochemical fraction.

What Rockstar Woman Entourage does not contain. No glycerin. No propylene glycol. No parabens. No fragrance compounds beyond the botanicals named on the label. Rockstar Woman Entourage is an oil-based formulation, which means it is not compatible with latex condoms — oil degrades latex. This is a label warning, not an asterisk: please pay attention to it.

Our theory: the local endocannabinoid system

Here is the theory. CB1 and CB2 receptors are expressed across the female reproductive system, and CB1 signaling is functional in vaginal tissue in a murine model. A full-spectrum hemp extract, with CBD as the dominant cannabinoid, may influence the endocannabinoid signaling there, alongside copaiba's β-caryophyllene, the CB2-selective agonist documented in the published cannabinoid literature[8]; and a supporting fraction of α-pinene, linalool, and the chamazulene in the chamomile extract.

On skin, the question is whether compounds cross the stratum corneum at all. On mucosa, the question is what they would meet: the endocannabinoid system in a tissue context that includes peripheral nerve endings, mucosal immune cells, and the epithelial cells themselves. CB1 activity in peripheral nerve endings modulates local nociceptive signaling[3]. CB2 activity on mucosal immune cells modulates inflammatory tone[3]. The phytochemical matrix that supports those receptor interactions, in the surrounding non-cannabinoid plant compounds, is the entourage hypothesis at the receptor level.

What this is not is a hormonal theory.

For women who have been through more

I declined chemotherapy after my colon surgery and started looking for what would help me thrive without it. I think about the women in my community who have made similar decisions, or who didn't have the choice — women whose tissue has been through breast cancer treatment, gynecologic cancer treatment, radiation, or surgical menopause, and who are now dealing with vaginal tissue that is both more reactive and more vulnerable than it was before.

For women in this position: please talk to your oncologist or your treating physician before adding any new product — botanical or otherwise — to your routine. There are real drug interactions to consider, particularly with certain chemotherapy agents and hormone-modulating treatments, and your treating physician knows your case in a way I cannot.

What the published literature supports strongly

  • β-caryophyllene functions as a selective CB2 receptor agonist with documented action in animal and in-vitro studies[8]
  • AKBA functions as a 5-lipoxygenase inhibitor[9]
  • CB1 and CB2 receptors are expressed across the female reproductive system[1][2][5]
  • CB1 receptor activation regulates vaginal secretion in a murine model, establishing functional cannabinoid signaling in vaginal tissue[4]
  • CB2 receptors are expressed on mucosal mast cells, macrophages, and peripheral nerve terminals, where activation modulates inflammatory and nociceptive signaling[3]
  • Full-spectrum cannabis extract and isolated CBD produce different dose-response profiles for inflammation in published comparative research[6]

Not yet measured in this tissue

  • Local tissue and systemic concentrations of any cannabinoid or terpene after a full-spectrum hemp botanical oil is applied to vulvovaginal tissue
  • AKBA concentration in the specific frankincense serrata CO₂ extract currently in production — supplier COA is by GC-MS; HPLC confirmation pending
  • Clinical outcomes — lubrication, comfort during intercourse, quality of life — in defined populations
  • Direct head-to-head comparison against other botanical options

We have a theory, and these are the studies we'd run if we had a million dollars. Who's with us?

  • A clinical pharmacokinetic study quantifying local tissue and systemic plasma concentrations of CBD and β-caryophyllene after application to vulvovaginal tissue
  • A clinical outcomes study in menopausal women — symptom resolution, comfort, adverse-event profile — with a stratified analysis for cancer-survivor participants
  • HPLC confirmation of AKBA in the specific frankincense serrata CO₂ source currently in production, and ongoing batch verification once confirmed
References
  1. [1] Luschnig P, Schicho R. Cannabinoids in Gynecological Diseases. Med Cannabis Cannabinoids. 2019;2(1):14-21. ↩
  2. [2] Horne AW, Phillips JA, Kane N, et al. CB1 Expression Is Attenuated in Fallopian Tube and Decidua of Women with Ectopic Pregnancy. PLoS ONE. 2008;3(12):e3969. ↩
  3. [3] Facci L, Dal Toso R, Romanello S, et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 1995;92(8):3376-3380. ↩
  4. [4] Murataeva N, Mattox S, Yust K, Straiker A. Cannabinoid Regulation of Murine Vaginal Secretion. Biomolecules. 2025;15(4):472. ↩
  5. [5] Sinclair J, Abbott J, Proudfoot A, Armour M. The Place of Cannabinoids in the Treatment of Gynecological Pain. Drugs. 2023;83(17):1571-1579. ↩
  6. [6] Gallily R, Yekhtin Z, Hanuš LO. Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol. Pharmacol Pharm. 2015;6(2):75-85. ↩
  7. [7] Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. ↩
  8. [8] Gertsch J, Leonti M, Raduner S, et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci USA. 2008;105(26):9099-9104. ↩
  9. [9] Effects of Frankincense Compounds on Infection, Inflammation, and Oral Health. Molecules. 2022. ↩